As sensors of invading microorganisms, Tolllike receptors (TLRs) are expressed not only on macrophages and dendritic cells (DCs) but also on epithelial cells. In the TLR family, TLR11 appears to have a unique feature that it is expressed primarily on epithelial cells, although it is also expressed on DCs and macrophages. Here we demonstrate that transcription of the TLR11 gene is regulated through two cis-acting elements, one Ets binding site and one IRF binding site. The Ets element interacts with the epithelial-specific transcription factors, ESE-1 and ESE-3; whereas, the IRF motif interacts with IRF-8. Thus, TLR11 expression on epithelial cells is regulated by the transcription factors that are, presumably, distinct from transcription factors that regulate the expression of TLRs in innate immune cells such as macrophages and DCs. Our results imply that the distinctive transcription regulatory machinery for TLRs on epithelium may represent a promising new avenue for the development of epithelia-specific therapeutic interventions.
As sensors of invading microorganisms, Tolllike receptors (TLRs) are expressed not only on macrophages and dendritic cells (DCs) but also on epithelial cells. In the TLR family, TLR11 appears to have a unique feature that it is expressed primarily on epithelial cells, although it is also expressed on DCs and macrophages. Here we demonstrate that transcription of the TLR11 gene is regulated through two cis-acting elements, one Ets binding site and one IRF binding site. The Ets element interacts with the epithelial-specific transcription factors, ESE-1 and ESE-3; whereas, the IRF motif interacts with IRF-8. Thus, TLR11 expression on epithelial cells is regulated by the transcription factors that are, presumably, distinct from transcription factors that regulate the expression of TLRs in innate immune cells such as macrophages and DCs. Our results imply that the distinctive transcription regulatory machinery for TLRs on epithelium may represent a promising new avenue for the development of epithelia-specific therapeutic interventions.
The expression and function of Toll-like receptor (TLR) genes in innate immune cells have been studied extensively (1) (2) (3) and the mechanisms that regulate TLR expression in these cells have been well defined (4, 5) . For instance, TLR2 can be upregulated by LPS, peptidoglycan and mycobacteria in macrophages and DCs, and the induction of TLR2 is mainly controlled by NF-κB and Sp1 transcriptional factors (6) (7) (8) . The murine TLR4 gene is highly expressed on macrophages and is regulated by the myeloid specific Ets transcription factor PU.1 (9) . TLR9 is predominantly expressed by dendritic cells (DCs) and macrophages (10, 11) and can be induced by type I interferons (IFNs), Signal Transducers and Activators of Transcription 1 (STAT1), and two IFN regulatory factors (IRF-1 and IRF-2) that mediate TLR9 up-regulation through IFN regulatory factor-element (ISRE/IRF-E) binding sites within the TLR9 promoter (12) . Collectively, these studies reveal the critical role of transcription factors in the regulation of TLR expression and function in cells of the innate immune system.
Epithelial cells not only provide the first physical barrier to infection, but they also contribute actively to innate immunity against invading microbes through pattern recognition receptors that recognize conserved molecular patterns present in microorganisms (13, 14) . It is clear that epithelial cells express functional TLRs; however, these epithelial TLRs display different sensitivity to their cognate ligands from the TLRs expressed on DCs and macrophages (15) (16) (17) . This difference in sensitivity is poorly understood (18) (19) (20) . Still, one clearly recognizable difference is the varied expression levels of TLRs, which might be controlled by distinct transcriptional regulators of individual cell types.
We previously demonstrated that TLR11, which is different from other TLRs, is primarily expressed in urinary tract epithelial cells (21). We hypothesize that the specific expression pattern of TLR11 might be controlled and regulated by different transcriptional factors that differ from those that regulate other TLRs in myeloid innate immune cells. Therefore, we cloned the murine TLR11 promoter and analyzed transcriptional regulation of the TLR11 gene. We found that the epithelium-specific Ets factors, ESE-1 and ESE-3, along with IRF8, control and regulate TLR11 expression in epithelial cells.
EXPERIMENTAL PROCEDURES
Cell lines and reagents-Renca (a kidney epithelial cell), Raw264.7 and HEK293 cells were purchased from ATCC. MLE15 was a gift from Dr. Scott Evans (University of Texas, MD Anderson Cancer Center). All cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% (v/v) heatinactivated fetal bovine serum (HyClone), 100 U/ml penicillin, and 100 µg/ml streptomycin at 37 o C in a 5% CO 2 incubator. Oligonucleotides were synthesized by Integrated DNA Technologies (Coralville, IA). Anti-IRF8 (sc-13043) and anti-ESE1 (sc-17306) antibodies for supershift analyses and ChIP assay were purchased from Santa Cruz Biotechnology. AntiFlag M2 antibody was from Sigma. The urinary pathogenic E. coli 8NU strain (21) was frozen in 1 ml aliquots in 10% glycerol at -80 o C at 2 x 10 8 CFU/ml. The frozen aliquots were thawed, and bacteria were heat-killed before each use.
Isolation of total RNA and RT-PCR and realtime PCR-Total RNA was isolated with TRIzol reagent (Invitrogen). cDNA was prepared by Oligo(dT) [12] [13] [14] [15] [16] [17] [18] and reverse transcriptase SuperScript II from Invitrogen with 2 µg of DNase I-treated total RNA. One µl of cDNA was amplified using primers shown in Table I . PCR parameters were as follows: denaturation at 94°C for 3 min was followed by 25-35 cycles at 94°C for 20 s, at 57°C for 20 s, and at 72°C for 30 s. The PCR products were subjected to electrophoresis in 1.5% agarose gels, visualized under UV light after ethidium bromide staining, and then imaged. The amplified products were sequenced to confirm their identity. For real-time PCR, 2 µl of the cDNAs was added to an 18-µl PCR assay mixture containing 0.5 M each primer and 1 µl Brilliant SYBR® Green QPCR Master Mix (Stratagene). PCR was conducted with the MyiQ Single Color Real-Time PCR Detection System (BioRad) using the following conditions: hot start activation at 95 °C for 10 min followed by 40 cycles of 95 °C for 15 s, 55 °C for 30 s, and 72 °C for 30 s. Two sets of PCR assays were performed for each sample using the primers listed in Table 1 . The threshold cycle number for TLR11 was normalized to that of β-actin, and the resulting value was converted to a linear scale. All assays were performed at least three times from independent RNA preparations.
RNA ligase-mediated 5' RACE-PCR-To
determine the transcription start site, we performed 5' RACE-PCR with the First Choice RLM-RACE Kit (Ambion). MLE15 cell RNA was first treated with calf intestinal phosphatase to remove free 5-phosphates from all RNA molecules. The RNA was then treated with tobacco acid pyrophosphatase to remove the cap structure, leaving a 5'-monophosphate. A 45 base pair RNA adapter oligonucleotide was ligated to 10 µg of the treated RNA using T4 RNA ligase. A randomprimed reverse transcription reaction was performed using M-MLV Reverse Transcriptase and then followed by nested PCR to amplify the 5' end of murine TLR11. The gene-specific primers are listed in Table I . The PCR product was cloned into pJET1.2/blunt cloning vector (Fermentas) and sequenced.
Cloning and Sequencing of the 5'-Flanking
Region of TLR11 Gene-We performed PCR amplification in a mouse genomic DNA using the murine TLR11-specific primers to identify the putative murine TLR11 5' proximal promoter. An approximate 2.0-kb fragment that contains the immediate 5'-flanking TLR11 sequence of the putative murine TLR11 promoter (Genbank: 209865968) was amplified using the Expand High Fidelity PCR system (Roche Applied Science) and the primers T11PS/T11PAS-1929 (Table I) . This 2.0-kb fragment was subcloned into the pGL3-basic vector (Promega). The complete sequence was determined with autosequencing by the Protein and Nucleic Acid Chemistry Facility at Baylor College of Medicine in Houston. Constructs p-812/+71, p-400/+71, p-171/+71 and p-103/+71 were generated by PCR using oligonucleotide  pairs  T11PS/T11PAS-812,  T11PS/T11PAS-400, T11PS/T11PAS-171 and  T11PS/T11PAS-103, respectively (Table I) Table I . All PCR products were gel-purified (Qiagen) and cloned into the mammalian expression vector pCMVTag2B (Stratagene). The PCR products were verified by sequencing then further confirmed by immunoblotting using an anti-Flag antibody (Sigma). The plasmids used for transient transfection were isolated and purified using the endotoxin-free Plasmid Midi Kit from Qiagen.
Transient transfections and luciferase assay-
All transfections were performed in triplicate in 24-well plates. Approximately 2 x 10 5 cells per well were seeded 24 h before transfection. Following the manufacturer's instructions, plasmids were transfected into cells using lipofectamine 2000 (Invitrogen). Briefly, 0.8 µg of reporter plasmids plus 0.05 µg of pCMV-LacZ vector were diluted with Opti-MEM and then mixed with diluted lipofectamine 2000. After 20 min incubation at room temperature, the mixtures were added to each well. At 24 h post-transfection, cells were either analyzed for luciferase activity or further challenged with different TLR agonists or other stimuli at the treatment times specified. Luciferase assays were performed using the Luciferase Assay System (Promega); β-Galactosidase activity was used as an internal control. Each experiment was conducted at a minimum of three times. Nuclear extracts and electrophoretic mobility shift assay (EMSA)-Nuclear extracts of MLE15 cells were prepared as previously described (21). Briefly, MLE15 cells were harvested by scraping in PBS, pelleted and then lysed in 500 µl of lysis buffer containing 0.5% NP-40, 10mM HEPES, 10mM KCl, 1.5 mM MgCl 2 , 0.5mM DTT, 1 mM Na 3 VO 4 and protease inhibitor cocktail (Roche Applied Science). Intact nuclei were pelleted by centrifugation at 12,000 g at 4 o C for 5 min and lysed in 150 µl of nuclear lysis buffer containing 20mM HEPES (pH 7.5), 25% glycerol, 0.42M NaCl, 0.2mM EDTA, 1 mM Na 3 VO 4 and protease inhibitor cocktail (Roche Applied Science). The protein concentration was determined by BCA assay (Pierce). The double-stranded DNA probes used in gel mobility shift assays are shown in Table I . EMSA was performed using Gel Shift Assay Systems (Promega). Briefly, 2.5 µg of nuclear extract was incubated with 10 ng of each labeled probe in binding buffer containing 0.5 mM EDTA, 0.5 mM DTT, 4% glycerol, 1 mM MgCl 2 , 50 mM NaCl, and 10 mM Tris-HCl (pH 7.5); then incubated for 20 min at room temperature. To demonstrate the sequence-specific binding, some of the reactions contained a 100-fold excess of the same unlabeled probe, and other unlabeled probes were used to determine specific and nonspecific binding. Furthermore, specific antibodies against ESE-1, IRF-8, or anti-Flag/ESE-3 for supershift assay were included in other reactions. The reaction mixtures were then separated in a 6% nondenaturing polyacrylamide gel at room temperature in 0.5 x TBE buffer at 100 V for 3 h. The gel was transferred to Whatman 3M paper, dried, and exposed to X-ray film overnight at -70°C with an intensifying screen. The probes used for EMSA are listed in Table I . Supershift analyses were performed as described (22).
ChIP assay-The chromatin immunoprecipitation (ChIP) assay was performed using the ChIP assay kit from Upstate Biotechnologies (Lake Placid, N.Y.). The cells (1 x 10 6 ) were fixed with 1% formaldehyde for 10 min and the chromatin was fragmented by sonication to yield fragments between 200 bp and 1000 bp, and 10 µl of the chromatin solution was saved as input. One µg of antibody or control immunoglobulin G was added to tubes containing 900 µl of chromatin solution. After incubation, the by guest on October 5, 2017 http://www.jbc.org/ Downloaded from antibody complexes were captured with protein Aagarose beads and subjected to serial washes. The chromatin fraction was further extracted, and the cross-linked chromatin was reversed at 65°C in the presence of 200 mM NaCl. The DNA was then purified using chloroform-isoamyl alcohol. The PCR primers used to amplify the endogenous TLR11 promoter were as follows 5'-GGGAAATGACACCAGGGCAACG -3' and reverse 5'-GCCCTGGGGGTGGAAGTAAGAGAA -3'. PCR products were then run on an agarose gel, stained with ethidium bromide, and photographed.
Statistical analysis-Results are expressed as means ± S.D. and are representative of at least three separate experiments. The two-sample t-test was used to determine statistical differences in the means of two columns. A P-value of less than 0.05 was considered to be statistically significant.
RESULTS

Determination of transcription start sites of TLR11 gene.
We previously demonstrated that TLR11 is primarily expressed by the urinary tract epithelial cells and TLR11 expression in epithelial cells appears to be stronger than in typical myeloid innate immune cells such as macrophages and DCs (21). We next examined the expression level of TLR11 mRNA in several mouse cell lines. RT-PCR results showed that TLR 11 mRNA was also highly expressed in mouse renal epithelial cell line Renca and lung epithelial cell line MLE15 (Fig. 1A) .
To understand the molecular mechanism underlying this epithelial expression feature of TLR11 gene, we analyzed the transcriptional regulation of TLR11 gene.
To facilitate the cloning of the TLR11 promoter, the transcription initiation site of the murine TLR11 gene was determined by RNA ligase-mediated rapid amplification of cDNA 5' ends (RLM-RACE) PCR using mRNA isolated from MLE15 cells, which highly expressed TLR11 (Fig. 1A) . The reverse primer was oligonucleotides that were complementary to the nucleotide position 145 bp downstream of the reported TLR11 mRNA sequence (Genbank: AY531552). The gene structure and the strategy designed for the 5'-RACE PCR are shown in Figure 1B . After RLM-RACE PCR, only one specific 211 bp product was obtained (Fig. 1B,C ). This PCR product was then cloned and sequenced.
The sole transcriptional start site was mapped 66 bp upstream of the adenine residue within the first translation start codon (Fig. 1B,C) . The mRNA transcription initiation site is designated as +1 in the numbering of the nucleotide sequence throughout this study.
Cloning and sequencing of the murine TLR11 promoter. Based on the determined location of the transcriptional start site (TSS), we then performed PCR amplification in a mouse genomic DNA as described in Experimental Procedures and cloned an approximate 2 kb fragment, a region spanning 1929 bp upstream to 71 bp downstream of the TSS. Nucleotide sequence analysis of the 5'-flanking region of the murine TLR11 gene (Genbank: FJ264503) revealed that no canonical TATA box was present ( Fig. 2A) . However, we identified several potential DNA-binding motifs in the promoter region, including two adjacent interferon response factor (IRF) binding sites and one Ets binding site ( Fig. 2A,B) .
Identification of cis-acting elements within the TLR11 gene promoter. Progressive 5' deletions of
TLR11 gene promoter constructs were generated to determine DNA transcription regulatory elements (Fig. 2B) . All constructs were then transiently transfected into the kidney epithelial Renca and the lung epithelial MLE15 cells. Luciferase activity was normalized for transfection efficiency by co-transfection with a LacZ vector, and results for individual cell lines were compared relative to the activity of the promoter-less pGL3-basic vector. Progressive 5' deletions of TLR11 gene promoter constructs revealed a pattern of functional activity in the transfected Renca and MLE15 cells (Fig. 2B) . The highest level of luciferase activity in MLE15 cells was associated with the p-236 fragments. Fragments larger than -1393 bp resulted in less luciferase activity, suggesting that the region from -1393 to -1929 bp contained negative regulatory elements. In contrast, additional deletions from -236 to -171 bp led to a remarkable reduction of the activity specifically in MLE15 and Renca cells (Fig. 2B) We previously demonstrated that TLR11 is expressed in epithelial cells and recognizes the urinary pathogen E. coli (UPEC) (21). The effects of this UPEC 8NU and other TLR ligands including LPS, PGN, flagellin and CpG DNA on TLR11 gene promoter activity were examined using Renca and MLE15 cells transfected with the TLR11 promoter constructs. After the cells were treated with the TLR ligands such as LPS and flagellin, luciferase activity levels remained almost unchanged (data not shown). Treatment with the lysate of 8NU only marginally increased the promoter's activity (Supplemental Fig. 1 ) and mRNA level of TLR11 (Supplemental Fig. 2 ) perhaps because the lysate can also induce the activation of inhibitors.
To pinpoint the functional significance of the potential transcription factor binding sites within the region of -236 to -171 bp, including IRF-E1, IRF-E2 and Ets sites, we used site-directed mutagenesis to mutate each of these sites, and then assayed their effects on luciferase activity in MLE15 cells (Fig. 3) . Disruption of the IRF-E1 and Ets sites dramatically impaired the p-236 promoter's activity by approximately 70 to 80 percent. In contrast, mutation of the IRF-E2 binding site did not affect TLR11 promoter activity (Fig. 3) . Thus, IRF-E1 and Ets elements act as essential cis-elements within the TLR11 promoter, because they are necessary to reach the maximal transcriptional activity.
Identification
of transcription factors responsible for the essential cis-acting IRF element. To identify the potential important transcription factors responsible for the IRF-E1 cis-acting element of the TLR11, the p-236 TLR11 promoter, which exhibits maximal luciferase activity, was co-transfected with various IRF expression vectors into MLE15 cells. As shown in Figure 4A , overexpression of IRF8 increased the transcription activity of the TLR11 promoter by 4-fold. In contrast, overexpression of other factors in the IRF family failed to accomplish such activation. Furthermore, the increase of promoter activity by IRF8 was dose-dependent (Fig. 4B) . Consistent with the idea that the IRF-E1 binding site is an essential cis-acting element, the promoter with this binding site mutation failed to become activated by IRF8 (Fig. 4C) . To the contrary, the mutation of IRF-E2 did not affect the ability of IRF8 to activate the TLR11 promoter.
To test whether IRF8 interacts directly with the IRF binding sites, a gel electrophoretic mobility shift assay (EMSA) was performed. Oligonucleotides corresponding to the binding site from IRF-E1 in the TLR11 promoter were designed (Table I) . According to EMSA, the mobility of each labeled DNA probe was altered in the presence of nuclear protein prepared from MLE15 cells (Fig. 4D) . The binding specificity of each probe was verified by supershift when we used anti-IRF8 anitibody or added excessive unlabeled oligonucleotide competitor (Fig. 4D) .
To further confirm the complex formation between IRF-E1 and IRF8 in TLR11 promoter, a ChIP assay was performed in MLE15 cells. Overnight immunoprecipitation of chromatin-bound DNA using antibodies against IRF8 and IgG was followed by PCR using primers that amplified the promoter region from -116 to -294 bp which includes the two IRF binding sites. As shown in Figure 4E , anti-IRF8 antibody was capable of immunoprecipitating the TLR11 promoter fragment containing the two IRF binding sites (Fig. 4E, lanes  4) ; however, immunoprecipitation using anti-IgG failed to produce a PCR product (Fig. 4E, lane 3) , indicating that IRF8 directly interacted with TLR11.
Identification of epithelial specific Ets transcription factors responsible for the essential cis-acting Ets element.
To identify the potential transcription factors that interact directly with the Ets cis-acting element in proximal TLR11 promoter, we overexpressed Ets transcription factors, including Ets1, Ets2, Pu.1 as well as epithelial specific ESE1-3, together with p-236 bp TLR11 promoter construct in MLE15 cells. As shown in Figure 5 , two epithelial-specific factors, ESE-1 and ESE-3, increased the promoter activity by 4-fold (Fig. 5A ) and in a dose-dependent pattern (Fig. 5B) . However, other members of the Ets transcription factor family such as PU.1 failed to induce promoter activation in MLE15 cells (Fig.5A) . Moreover, the Ets cis-acting element was indispensable for ESE1/3-mediated transcription activity, since the mutated Est binding site promoter did not respond to ESE1/3 (Fig. 5C) .
To test whether ESE1/3 interacts directly with the Ets binding site in the TLR11 promoter, gel EMSA was performed again. The Ets cis-acting element formed specific complexes with nuclear protein extracted from MLE15 cells (Fig. 5D,E) . The specificity of this binding was confirmed when complex formation was inhibited by the addition of an excess of the respective, unlabeled oligonucleotide competitor. Furthermore, the specific complex was also supershifted by ESE1 antiserum (Fig. 5D ) and anti-Flag antibody substituted for ESE-3 ( Fig. 5E ), because no anti-ESE-3 specific antibody is available.
To further demonstrate the in vivo interaction between ESE1/3 and Ets binding site in the TLR11 promoter, we also performed a ChIP assay. MLE15 cells were cross-linked with formaldehyde. Nuclear extracts were sonicated and incubated with anti-ESE-1 or anti-FLAG antibody, respectively. The interactions of proteins with the TLR11 promoter were determined by PCR directed to the -116 to -294 region of the promoter. As shown in Fig. 5F and 5G, ESE-1 and FLAG-fused ESE-3 formed complex with the TLR11 promoter region, indicating that both ESE-1 and ESE-3 did interact with TLR11 promoter.
ESE-1 and ESE-3 are important for the transcription of TLR11 in epithelia cells.
To further confirm the roles of ESE-1, ESE-3 and IRF-8 in the regulation of TLR11 in vivo, siRNAs assays were performed to knock down the expression of these transcriptional factors in MLE15 cells. The siRNAs were able to knock down endogenous ESE-1/3 and IRF-8 expression respectively as shown by the realtime PCR assay (Supplemental Fig.3) . Using these cells, we subsequently performed real-time RT-PCR to quantify the mRNA level of TLR11. We found the expression of TLR11 was reduced in the cells with knockdown of either ESE-1 or ESE-3. However, the expression level of TLR11 only changed marginally in the cells after knocking down IRF8 (Fig. 6A) , which may indicate that other partners besides IRF-8 are also involved in this promoter context. Moreover, when both ESE-1 and ESE-3 were simultaneously knocked down, the expression of TLR11 was more dramatically decreased than it was when either ESE-1 or ESE-3 was knocked down alone (Fig. 6A) . We also co-transfected the p-236 TLR11 promoter with the various siRNAs into MLE15 cells and determined the promoter luciferase activity after 24 hours. The TLR11 promoter activity also demonstrated the same trend with the expression of TLR11 (Fig. 6B) . Thus, these results demonstrate the role of ESE-1 and ESE-3 in the regulation of endogenous TLR11 expression in epithelial cells.
DISCUSSION
TLR11 appears to be predominantly expressed in epithelial cells (21). Our present studies of the transcriptional regulation of TLR11 demonstrate that two cis-acting elements within murine TLR11 promoter, one Ets binding site and one IRF binding site, are required for maximal transcription of the murine TLR11 gene. The epithelium-specific Ets transcription factors, ESE-1 and ESE-3, along with IRF-8 appear to regulate the expression of TLR11 transcription in murine epithelial cells, implicating a distinct transcription regulatory machinery for TLRs that is unique to epithelial cells and may control infections therein.
Epithelial cells express several functional TLRs through which invading pathogens are identified and immune responses are elicited (15, 23, 24) . For instance, the subcellular localization of TLR4 in lung and intestinal epithelial cells is intracellular; this expression pattern is different from that found on macrophages and DCs (19, 25). In addition, TLR9 activation through apical and basolateral surfaces in intestinal epithelial cells promotes distinct immune responses. Basolateral TLR9 activation invokes inflammatory responses; whereas apical TLR9 simulation inhibits inflammation and induces tolerance, which proved to be important for the maintenance of colonic homeostasis and the regulation of inflammation (20). TLR5, a well-known cell surface TLR, seems to be restricted only to the basolateral membrane in epithelial cells (26).
Moreover, transcriptional regulation plays a key role in the control of TLR expression level, which may be a factor in the unique features of epithelial TLRs (22). The transcriptional regulation of TLRs in myeloid innate immune cells has been extensively studied and determined. TLR expression is generally regulated by NF-κB, Sp1 and PU.1 (a myeloid-specific transcription factor in the Ets family). The Ets transcription factor family consists of more than 30 members by guest on October 5, 2017 http://www.jbc.org/ Downloaded from that have a diverse range of functions (27). The Ets transcription factors share a conserved Ets domain that binds to purine-rich DNA sequences with a central GGAA/T core consensus, and they function as activators or repressors based on promoter context, cell type or growth cycle. In this family, the myeloid-specific member PU.1 has been reported to play a role in regulating the expression of TLRs including TLR1, TLR4, and TLR9(22,33). Although we found an Ets binding site within the crucial region of the TLR11 promoter, we failed to detect PU.1 binding to TLR11 promoter. Also, overexpression of PU.1 did not affect TLR11 promoter activity.
Considering that TLR11 is predominantly expressed in epithelial cells, we pursued the theory that epithelial-specific transcription factors in the Ets family control and regulate TLR11 promoter activity. ESE-1, ESE-2, and ESE-3 are the epithelial-specific Ets members (28). More importantly, ESE-1 was reported as a transcription mediator of inflammation that interacts with NF-κB to regulate the inducible nitric-oxide synthetase gene (29, 30). Our analysis of these epithelial-specific Ets transcription factors revealed that ESE-1 and ESE-3 bound specifically to the Ets cis-element in the TLR11 promoter region. However, we cannot exclude that other factors or members of the Ets family can bind to this site, since multiple complex formations were also detected with our EMSA protocol. The ChIP assay further confirmed the interaction between these epithelial-specific Ets transcription factors and TLR11 promoter in vivo.
Additionally, overexpression of ESE-1 and ESE-3 in MLE15 cells can upregulate the promoter activity of TLR11. The siRNA knockdown assay further demonstrated the essential role of ESE-1 and ESE-3 in the expression of TLR11 in MLE15 cells. It is known that ESE-1 basal expression is restricted in epithelial cells but not in resting macrophages; however, ESE-1 can be induced by LPS in macrophages and can upregulate murine TLR4 transcriptional activity (9) . Therefore, the role played by ESE-1 may be limited to activated macrophages. Here, we ascertained that the epithelial-specific Ets members, ESE-1 and ESE-3, control and regulate TLR11 expression in epithelial cells.
Elsewhere, ESE-3 was proposed as a candidate gene related to asthma susceptibility (31). Our previous report demonstrated that TLR11 recognizes a profillin-like protein in parasites (32) . Since more than 100 allergens such as various pollens possess profilin-like domains, these profilin-like allergens may function via a TLR such as TLR11. If so, this TLR could be regulated by ESE-3 and act to control sensitivity to asthma.
The IRF family of transcription factors, which also regulate TLR expression, have the capacity for direct mediation of TLR's action through IRF binding sites in TLR promoters (22, 33, 34) . For instance, both TLR3 and TLR9 can be induced by IFN-β via constitutively bound IRF-2 and recruitment of IRF-1 to the promoters (12, 34) . IFN-β and Poly IC can induce TLR7 expression that relies on IRF-1 binding to the TLR7 promoter (35) . Not surprisingly, all these TLRs (TLR3, TLR7, and TLR9) regulated by IFRs play a role in the recognition of viral infection (1) .
In the present study, we found an IRF-binding site within the crucial region of TLR11 promoter and then tested multiple IRFs in that context. However, only IRF-8 was identified with direct binding to the TLR11 promoter. IRF-8 is one of the transcription factors that regulate gene expression in response to pathogen-derived danger signals (36) . Although IRF-8 was shown to regulate IL-12 (36) , its relationship to the management of bacterial infection is still uncertain but might resemble that of TLR11, which recognizes bacterial infection. Supporting evidence for this concept is that IRF-8 controls and regulates TLR4 expression, which can recognize bacterial LPS (22). Additionally, a characteristic of IRF-8 (ICSBP) is its constitutive expression in B cells, pDCs, and monocytes (36) . Furthermore, we detected IRF-8 expression in MLE15 lung epithelial cells (data not shown).
IRF-8 generally does not bind to DNA by itself but can interact with other transcription factors of the IRF family, including IRF-1, IRF-2, PU.1 and E47 (37) . Interaction between IRF-8 and other IRF family members results in an increased binding to IRF binding sites. However, since we did not identify these partners of IRF-8 (including IRF-1, IRF-2, and PU.1) as regulators of TLR11 expression in epithelial cells, IRF-8 may utilize distinct mechanisms in different cell types.
In summary, our results document that the epithelium-specific Ets transcription factors, ESE- Labeled mouse Ets oligonucleotides were used in an electrophoretic mobility shift assay with nuclear proteins from MLE15 cells. Specific shift-bands for ESE-1 (D) and ESE-3/Flag (E) are indicated with a closed arrowhead. NE, nuclear extract; SC, 100× specific competitors; NSC, 100× nonspecific competitors. ** P<0.001 compared with the mock control. (F) Chromatin immunoprecipitation assay using MLE15 cell lysates and (G) MLE15 cells transfected with FLAG-ESE-3. Chromatin was immunoprecipitated using antibodies to ESE-1 (Fig. 5F, lane 4) or FLAG (Fig. 5G, lane 4 
